Apyx Medical Corp
APYX3.680USD
+0.190+5.44%
Market hours （ET）Quotes delayed by 15 min
139.18MMarket Cap
LossP/E TTM
More Details of Apyx Medical Corp Company
Apyx Medical Corporation is an advanced energy technology company. The Company's segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment's product portfolio consists of Helium Plasma Technology, which is marketed and sold as Renuvion in the cosmetic surgery market, and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment produces generators, medical devices, and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs. It specializes in the design, development, and manufacturing of electrosurgical equipment and medical devices.
Apyx Medical Corp Info
Ticker SymbolAPYX
Company nameApyx Medical Corp
IPO dateJul 22, 1983
CEOGoodwin (Charles D)
Number of employees220
Security typeOrdinary Share
Fiscal year-endJul 22
Address5115 Ulmerton Rd
CityCLEARWATER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33760-4004
Phone18005372790
Websitehttps://apyxmedical.com/
Ticker SymbolAPYX
IPO dateJul 22, 1983
CEOGoodwin (Charles D)
Company Executives of Apyx Medical Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Stavros G. Vizirgianakis
Mr. Stavros G. Vizirgianakis
Independent Chairman of the Board
Independent Chairman of the Board
1.75M
--
Mr. Moshe Citronowicz
Mr. Moshe Citronowicz
Senior Vice President
Senior Vice President
456.50K
--
Mr. Lawrence J. (Larry) Waldman, CPA
Mr. Lawrence J. (Larry) Waldman, CPA
Lead Independent Director
Lead Independent Director
42.90K
--
Mr. Matthew C. (Matt) Hill
Mr. Matthew C. (Matt) Hill
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
8.50K
--
Mr. Shawn David Roman
Mr. Shawn David Roman
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Ms. Wendy Levine
Ms. Wendy Levine
Independent Director
Independent Director
--
--
Mr. Charles D. Goodwin, II
Mr. Charles D. Goodwin, II
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Stavros G. Vizirgianakis
Mr. Stavros G. Vizirgianakis
Independent Chairman of the Board
Independent Chairman of the Board
1.75M
--
Mr. Moshe Citronowicz
Mr. Moshe Citronowicz
Senior Vice President
Senior Vice President
456.50K
--
Mr. Lawrence J. (Larry) Waldman, CPA
Mr. Lawrence J. (Larry) Waldman, CPA
Lead Independent Director
Lead Independent Director
42.90K
--
Mr. Matthew C. (Matt) Hill
Mr. Matthew C. (Matt) Hill
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
8.50K
--
Mr. Shawn David Roman
Mr. Shawn David Roman
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Domestic
7.78M
68.37%
International
3.60M
31.63%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
8.14%
Archon Capital Management LLC
8.00%
Vanderfelt (William Weeks)
7.70%
Royce Investment Partners
6.03%
Vizirgianakis (Stavros G)
4.26%
Other
65.87%
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
8.14%
Archon Capital Management LLC
8.00%
Vanderfelt (William Weeks)
7.70%
Royce Investment Partners
6.03%
Vizirgianakis (Stavros G)
4.26%
Other
65.87%
Shareholder Types
Shareholders
Proportion
Hedge Fund
17.02%
Individual Investor
13.42%
Investment Advisor
11.62%
Investment Advisor/Hedge Fund
8.99%
Private Equity
0.37%
Family Office
0.23%
Research Firm
0.10%
Venture Capital
0.05%
Other
48.19%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
93
15.65M
47.11%
--
2025Q3
106
16.17M
54.10%
-179.30K
2025Q2
111
16.35M
54.58%
+38.20K
2025Q1
115
16.92M
61.27%
-6.24M
2024Q4
121
17.05M
55.05%
+3.13M
2024Q3
126
13.93M
65.05%
-228.66K
2024Q2
141
15.10M
68.01%
-305.66K
2024Q1
168
15.41M
70.58%
-9.04M
2023Q4
180
18.49M
72.63%
-941.37K
2023Q3
175
19.43M
74.54%
-988.75K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nantahala Capital Management, LLC
3.34M
8.83%
+80.00K
+2.46%
Jun 30, 2025
Archon Capital Management LLC
3.28M
8.68%
-15.26K
-0.46%
Jun 30, 2025
Vanderfelt (William Weeks)
3.16M
8.35%
--
--
Jun 23, 2025
Royce Investment Partners
2.44M
6.45%
-85.76K
-3.40%
Jun 30, 2025
Vizirgianakis (Stavros G)
1.75M
4.62%
--
--
Jun 23, 2025
The Vanguard Group, Inc.
1.48M
3.9%
--
--
Jun 30, 2025
Silverberg Bernstein Capital Management, LLC
986.50K
2.61%
+89.77K
+10.01%
Sep 30, 2025
Commonwealth Financial Network
663.54K
1.75%
+78.00K
+13.32%
Jun 30, 2025
Horizon Kinetics LLC
615.00K
1.63%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
495.99K
1.31%
+6.87K
+1.40%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
Avantis US Equity ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
Avantis US Equity ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Apyx Medical Corp?
The top five shareholders of Apyx Medical Corp are:
Nantahala Capital Management, LLC holds 3.34M shares, accounting for 8.83% of the total shares.
Archon Capital Management LLC holds 3.28M shares, accounting for 8.68% of the total shares.
Vanderfelt (William Weeks) holds 3.16M shares, accounting for 8.35% of the total shares.
Royce Investment Partners holds 2.44M shares, accounting for 6.45% of the total shares.
Vizirgianakis (Stavros G) holds 1.75M shares, accounting for 4.62% of the total shares.
Nantahala Capital Management, LLC holds 3.34M shares, accounting for 8.83% of the total shares.
Archon Capital Management LLC holds 3.28M shares, accounting for 8.68% of the total shares.
Vanderfelt (William Weeks) holds 3.16M shares, accounting for 8.35% of the total shares.
Royce Investment Partners holds 2.44M shares, accounting for 6.45% of the total shares.
Vizirgianakis (Stavros G) holds 1.75M shares, accounting for 4.62% of the total shares.
What are the top three shareholder types of Apyx Medical Corp?
The top three shareholder types of Apyx Medical Corp are:
Nantahala Capital Management, LLC
Archon Capital Management LLC
Vanderfelt (William Weeks)
Nantahala Capital Management, LLC
Archon Capital Management LLC
Vanderfelt (William Weeks)
How many institutions hold shares of Apyx Medical Corp (APYX)?
As of 2025Q4, 93 institutions hold shares of Apyx Medical Corp, with a combined market value of approximately 15.65M, accounting for 47.11% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -6.99%.
What is the biggest source of revenue for Apyx Medical Corp?
In FY2025Q2, the -- business generated the highest revenue for Apyx Medical Corp, amounting to -- and accounting for --% of total revenue.
